UPAR Targeting Peptide for Peroperative Optical Imaging of Invasive Cancer

The EPO published EP3733215A1 for Fluoguide A/S for a UPAR targeting peptide for peroperative optical imaging of invasive cancer. The patent claims the peptide composition, methods of use, and diagnostic applications in cancer surgery. Inventors are Andreas Kjaer and Morten Persson. The designated states include AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

This patent grant affects Fluoguide A/S by providing exclusive rights to the UPAR targeting peptide technology for cancer imaging applications in designated European states. Competitors developing similar peroperative imaging agents may need to design around this patent or seek licensing arrangements. Healthcare institutions and surgical centers utilizing optical imaging technologies should verify appropriate licensing or freedom-to-operate for peroperative cancer imaging procedures.